Fat-busting Neothetics files $63M IPO; Dupilumab starts PhIII; Amgen sets up an emergency Ebola team for ZMapp;

@FierceBiotech: PureTech reels in $55M to fund new biotech bets. News | Follow @FierceBiotech

@JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce

@DamianFierce: ICYMI Friday: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Article | Follow @DamianFierce

@EmilyMFierce: TesoRx licenses oral low-T drug to Aspen amid FDA crackdown. Story | Follow @EmilyMFierce

> San Diego-based Neothetics has filed for a $63 million IPO. The biotech is developing LIPO-202, headed into Phase III studies as a new approach to reducing abdominal fat. The treatment is an injectable formulation of salmeterol xinafoate. SEC

> Amgen ($AMGN) has assigned a group to investigate more efficient ways to make ZMapp, a cocktail of antibodies developed by San Diego-based Mapp Biopharmaceutical to fight Ebola. ZMapp has been using a plant-based model that may work better in the long run, but Amgen says its approach using Chinese hamster ovary cells may be better for emergency use, as the production facilities are already well established. Report

> Sanofi ($SNY) and its close partner Regeneron ($REGN) has begun a Phase III study of dupilumab for atopic dermatitis. Release

Medical Device News

@FierceMedDev: Quest and LabCorp won't accept blood samples from suspected  patients. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI last week: Boston Scientific wins CE mark for MRI-friendly pacemaker products. Report | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. FierceDrugDelivery story | Follow @MichaelGFierce

> Nanodevices could be unleashed by DNA-brick self-assembly. Article

> Abbott seals a deal with Zeiss to sell cataract surgery products. Report

Pharma News

@FiercePharma: Top-read special report over the weekend: The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce:  India's Ascend sold laxatives to urea creams the #FDA never approved. It's now headed for incineration. Article | Follow @EricPFierce

@CarlyHFierce: Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results. Press release | Follow @CarlyHFierce

> Addiction-riddled Kentucky out for blood in $1B suit against OxyContin-maker Purdue. Article

> Shire CFO jumps ship as post-AbbVie deal talk heats up. Report

> Thumbing its nose at critics, Valeant touts Q3 growth, hikes forecasts. More

CRO News

> Charles River debuts new testing tech for quality control. News

> Big CROs are booming, but can it last? Item

> A glitch in bioequivalence software puts trial results in doubt. More

> INC signs on to help Provectus get its regulatory act together. Article

> PPD pairs off with Sellas to pick up the pipeline pace. Story

Biotech IT News

> Regeneron allies with DNAnexus on 100,000 exomes project. News

> Report: Novo Nordisk to file for IT unit IPO in coming days. Item

> Researchers join forces to build database of 50M genetic variants. More

> Genomics England picks 10 firms for next round of bioinformatics talent contest. Story

> EMA to discuss possible glitch in Thermo bioequivalence software. Article

Animal Health News

> Blaze wins NCI funding for 'tumor paint' after successful dog study. News

> Canadian Government funds Elanco genomics project. Story

> FDA cracks down on Little City Dogs' compounded copies of popular pet meds. Article

> Report: Pork industry group responds to antibiotic documentary with online campaign. More

> Five questions for Aratana CEO Steven St. Peter. Editor's Corner

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.